NASDAQ · Biotechnology

DMAC (DMAC) Stock

$6.65 -1.27% NASDAQ: DMAC Healthcare

Valuation

MetricValue
Price$6.65
Market Cap$358.56M
P/E Ratio-8.09
P/B Ratio5.45
P/S Ratio0.00
EPS (TTM)$-0.70
52-Week High$10.42
52-Week Low$3.48
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-58.93%
ROA-54.10%
ROCE-60.71%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio12.20

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-14.0M$-14.0M$-21.0M$-27.0M$-34.0M
Net Profit$-14.0M$-14.0M$-19.0M$-24.0M$-33.0M
EPS$-0.65$-0.52$-0.60$-0.60$-0.70
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$46.0M$34.0M$54.0M$46.0M$61.0M
Total Liabilities$2.0M$3.0M$3.0M$6.0M$5.0M
Cash$5.0M$5.0M$5.0M$3.0M$16.0M
Borrowings$0$0$0$0$0

Latest News

DiaMedica Therapeutics Doses First Patients in Phase 2 Fetal Growth Restriction Trial MT Newswires · Jun 23, 2026 DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction Business Wire · Jun 23, 2026 DiaMedica Therapeutics Receives US FDA Guidance on DM199 Nonclinical Requirements MT Newswires · Jun 16, 2026 DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program Business Wire · Jun 16, 2026 DiaMedica (DMAC) Q4 2025 Earnings Transcript Motley Fool · Jun 1, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-12.0M$-12.0M$-19.0M$-22.0M$-29.0M
Investing Cash Flow$-21.0M$11.0M$-18.0M$9.0M$-2.0M
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$-3.0M$0$0$-2.0M$13.0M
Free Cash Flow$-12.0M$-12.0M$-19.0M$-22.0M$-29.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-10.15%
Quick Ratio9.11
Interest Coverage—
Return 1Y32.43%
Return 3Y96.54%
Return 5Y98.96%

Ownership

Insiders Held27.74%
Institutions Held37.85%
Institutions Float Held52.38%
Institutional HolderSharesReport Date
Cooperman, Leon G.2,020,0002026-03-31
Blackrock Inc.1,856,1872026-03-31
Millennium Management Llc935,5922026-03-31
Paragon Associates & Paragon Associates Ii Joint Venture875,0002026-03-31
Geode Capital Management, LLC780,5162026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ALT $3.03 -1.30% -2.31 $267.42M 0.00%
ANNX $5.37 +0.75% -3.71 $879.83M 0.00%
DBVTDBV Technologies S.A. $15.84 +0.83% -3.27 $378.92M 0.00%
DRTS $11.59 -5.08% -18.73 $1.05B 0.00%
DSGN $13.57 +2.80% -11.56 $847.54M 0.00%

About DMAC

DMAC is led by CEO Dietrich John Pauls, employs 27 people, headquartered in US, publicly traded since 2012.

DMAC stock trades at $6.65 with a market capitalization of $358.56M. The stock is valued at a price-to-earnings (P/E) ratio of -8.09, price-to-book of 5.45, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $3.48 and $10.42, and currently trades 36.2% below its 52-week high.

On profitability, DMAC generates a return on equity (ROE) of -58.93%, return on capital employed of -60.71%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides